"Technology Licence Cellestis holds the exclusive licence for Quantiferon technology from CSL Limited. This licence includes Quantiferon manufacturing and testing technology, all development data from clinical trials, and all associated information and intellectual property. The Quantiferon patents were registered in the name of CSIRO, and have been exclusively sub-licensed to Cellestis by agreement with CSL Limited and CSIRO."
Just a question:
Is there any caveat in the original licence agreements that prevents the Cellestis Board from selling this great bit of Australian biotechnology offshore without CSL and CSIRO approval?
I would be happier to have CSL act as a "white knight" with a competitive offer to take us back and keep the product Australian owned....Brian McNamee are you interested? Happy to consider an offer of CSL shares for my CST holding.
Also what would the attitude of the Foreign Review Board be to this proposed aquisition? Surely it cannot just let Cellestis go to an foreign company that essentially has little synergy to benefit what Cellestis already achieved. Taxpayer funds contributed to the original discoveries via the CSIRO and probably R & D grants and Tax concesions.
CST Price at posting:
$3.42 Sentiment: Hold Disclosure: Held
